FDA says Champaklal Maganlal Homeo Pharmacy's Bebelyn diarrhea and colic products are unapproved new drugs for infants.
What happened
FDA reviewed product labels that CMHP provided after a records request and reviewed websites selling the products. FDA found the labels and websites claim Bebelyn Diarrhea and Bebelyn Colic relieve diarrhea, colic, gas, bloating, cramps, or hiccups, with directions for children 3 months and older. FDA also cited a prior April 10, 2023 warning letter to CMHP for CGMP violations, including failure to demonstrate adequate identity testing of glycerin used in some products.
What FDA found
The Bebelyn Diarrhea and Bebelyn Colic products are unapproved new drugs because they are not generally recognized as safe and effective for their labeled uses and have no FDA-approved application.
FD&C Act sections 201(p), 505(a), 21 U.S.C. 321(p), 355(a)Offering these products for introduction into interstate commerce violates the law because they lack an approved drug application.
FD&C Act sections 301(d), 505(a), 21 U.S.C. 331(d), 355(a)The labels and websites make claims that the products treat diarrhea or colic symptoms, which shows they are intended for use as drugs.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)A prior FDA warning letter cited significant CGMP violations at CMHP, including failure to show adequate identity testing of glycerin used in some drugs, a component that can be contaminated with DEG or EG and cause lethal poisoning.
What FDA wants
FDA asks the companies to notify it in writing within 15 working days of the specific steps taken to correct the violations, including an explanation and related documentation. If corrective action cannot be completed in that time, they must state the reason for the delay and when it will be completed.
Who should pay attention
- distributors and retailers selling Bebelyn products
- brands using contract manufacturers for homeopathic children's drugs
- importers of homeopathic drug products labeled for pediatric use
This is a summary. Read the original letter on fda.gov.